VFA
SAGE

Virtus Fund Advisers’s Sage Therapeutics SAGE Stock Holding History

Virtus Fund Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$360K Buy
+2,187
New +$212K ﹤0.01% 388

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Virtus Fund Advisers's SAGE Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Sage Therapeutics (SAGE) in Q4 2017: 2,187 shares worth $360K. The stake represents ﹤0.01% of the portfolio and ranks #388 among its holdings.

224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • Virtus Fund Advisers held 2,187 shares of Sage Therapeutics worth $360K as of Q4 2017.
  • Sage Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Sage Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #388 holding.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.